FDA Bans Emcure Pharma’s India Plant

News
Article

FDA released news of the ban of Emcure’s Hinjewadi manufacturing plant after it determined the plant did not meet basic quality standards.

 

FDA announced a ban of Emcure Pharma’s India plant following an inspection of the facility by the agency, citing poor manufacturing quality standards, according to a report from Reuters on July 14, 2016.

According to Emcure's website, although its NJ plant is "designed and maintained to prevent cross-contamination and meet cGMP requirements," the company has eight other manufacturing locations, all of which are in India. Only five of its facilities, however, are approved by FDA, according to Emcure’s website. The company manufactures both tablets and injectables at its Hinjewadi site.

In February 2015, Sagent Pharmaceuticals recalled several lots of Atracurium Besylate Injection that were manufactured by Emcure due to sterility concerns, ultimately causing Sagent to transfer the manufacture of this product to its own facilities.

Source: Reuters

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.